Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Could This New Development Soon Buoy Eli Lilly and Novo Nordisk Stock?
07:15am, Sunday, 07'th Apr 2024
Novo Nordisk and Eli Lilly make medicines that target GLP-1, which figures in a number of ailments. A new study found that a similar drug could help treat Parkinson's.
Wegovy's heart benefits are not just linked with weight loss, new study suggests
04:16pm, Saturday, 06'th Apr 2024
People with obesity-related heart failure and diabetes can get substantial heart-health benefits from the popular obesity drug Wegovy, even if they don't shed a lot of weight on the medication, accord
Diabetes medication appears to slow progress of Parkinson's disease in French-backed trial
07:12am, Thursday, 04'th Apr 2024
A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson's disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others, the Ne
Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?
04:55am, Thursday, 04'th Apr 2024
Eli Lilly and Novo Nordisk have seen demand surpass supply of their weight loss drugs. Their revenues have soared thanks to these popular products.
3 Underappreciated Healthcare Stocks to Buy Now: April 2024
08:02pm, Wednesday, 03'rd Apr 2024
The healthcare sector is a constant source of innovation and growth. Yet, even amidst the spotlight on industry giants, a realm of underappreciated gems still exists.
Healthy Returns: Weight loss, diabetes drug ad spending tops $1 billion
01:33pm, Wednesday, 03'rd Apr 2024
Drugmakers spent big on ads for weight loss and diabetes drugs such as Wegovy and Ozempic. Meanwhile, the FDA approved the first AI diagnostic tool for sepsis.
Costco begins offering Novo Nordisk's Ozempic to members
01:02pm, Wednesday, 03'rd Apr 2024
Costco and its healthcare partner Sesame have started offering weight-loss drugs including Ozempic to Costco members. Under a $179 three-month prescription plan, members will have access to video cons
Biotech's Next Gold Rush: Weight-Loss Drugs
04:56pm, Tuesday, 02'nd Apr 2024
Biotech's next gold rush is weight-loss drugs. There is a dominance of NVO and LLY in this space for now, notes Rahul Jasuja.
Wall Street Analysts Think Novo Nordisk (NVO) Is a Good Investment: Is It?
10:31am, Tuesday, 02'nd Apr 2024
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
Healthcare stocks fade as obesity-drug optimism fades
08:59pm, Monday, 01'st Apr 2024
Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.
Here's Why Novo Nordisk (NVO) Fell More Than Broader Market
06:56pm, Monday, 01'st Apr 2024
Novo Nordisk (NVO) closed at $127.55 in the latest trading session, marking a -0.66% move from the prior day.
Is Novo Nordisk the Best Healthcare Stock for You?
06:14pm, Sunday, 31'st Mar 2024
Novo Nordisk's business is not only growing at a fast rate; it also generates impressive margins. Demand for its products is strong and could increase in the years ahead.
How Novo Nordisk built an empire selling diabetes and weight-loss drugs
10:00am, Sunday, 31'st Mar 2024
The popularity of Novo Nordisk's (NVO) blockbuster obesity drug Wegovy, and diabetes drug Ozempic, for weight loss, was so great in 2023 that it has been credited with propping up the entire economy o
Diversifying Into This Key Market Is 1 More Reason to Buy Novo Nordisk Stock
08:15am, Sunday, 31'st Mar 2024
Novo Nordisk is buying Cardior, a clinical-stage biotech that is developing heart disease drugs. Its cardiovascular disease pipeline will get a lot stronger as a result of the acquisition.
Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'
06:22am, Sunday, 31'st Mar 2024
Omega Therapeutics is a biotech company focused on developing programmable epigenomic mRNA medicines to control gene manifestation. The company's platform has applications in various diseases, includi
